AbbVie Insider Jeffrey Ryan Stewart Cashes Out $11.9M Near Record Highs
As seen on the 24/7 Wall St. homepage on November 12, 2026.
Jeffrey Ryan Stewart exercised options at $93.50 and $114.36 and sold all 40,619 of those shares at $293.60, a same-day $11.9 million cash-out that left his direct stake roughly halved. The sale lands with the stock near record highs on Skyrizi strength.
Continue ReadingShow less
On November 12, 2026, Jeffrey Ryan Stewart exercised two tranches of AbbVie options and immediately sold all 40,619 resulting shares. The same-day exercise-and-sell structure left nothing on the table, converting the full position into $11.9 million in cash.
The transaction represented roughly half of Stewart's direct stake in AbbVie, with the sale accounting for about 0.49% of his total holdings. Insiders who unload that proportion of their personal position in a single session are typically signaling that price is the primary motivation.
Sponsored
The timing is notable because the sale occurred with the stock trading near record highs, a level the card facts attribute to strength in Skyrizi, AbbVie's immunology drug. Selling into a peak is the clearest signal an insider can send about their near-term price expectations.
Shares acquired at $93.50 and $114.36 were liquidated at $293.60, so the gains embedded in those options were substantial before Stewart ever touched the open market. That kind of locked-in profit often accelerates the decision to sell.
Sources
Mentioned: ABBV